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This is an author version of the contribution published on: 6 Questa è la versione dell'autore dell'opera: 7 [Expert Opin Drug Discov, 9(4) , , DOI 10.1517 /17460441.2014 8 ovvero [Scutera S, Zucca M, Savoia D, 9, Informa Healthcare,2014, pagg. 353 -66] 9 The definitive version is available at: 10 La versione definitiva è disponibile alla URL: 11 [http://informahealthcare.com/doi/abs/10. 1517/17460441.2014.894974 ]   12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38 1. Introduction 1 Intercellular communication by means of secreted hormone-like molecules (pheromones) is an 2 important natural feature, which in different bacterial species is involved in bioluminescence, 3 virulence, biofilm formation, antibiotic production, competence, conjugation, swarming, motility, 4 and sporulation [1] . For most pathogenic bacteria, the ability to implement this kind of multicellular 5 coordination is critical for disease pathogenesis and host colonization. Quorum sensing (QS) is the 6 term used to describe a density-dependent intercellular communication that allows a coordinated 7 multicellular behaviour in prokaryotes, based on the constitutive production and secretion of small 8 molecules defined quorum sensors or autoinducers (AI) [2] . When the AI concentration reaches a 9 critical detection threshold that depends upon bacterial population density (quorum), the AI 10 interaction with species-specific receptors triggers a signal transduction cascade leading to an 11 alteration in gene expression. The production of a number of virulence factors involved in bacterial 12 pathogenesis and in the formation of bacterial sessile communities called biofilms is based on this 13 mechanism. Biofilms account for more than 80% of human infections [3] and their treatment is 14 highly problematic, because sessile bacteria are up to 1000 times more resistant to antibiotics in 15 comparison to their planktonic counterparts, and are less exposed to the host immune system [4] . 16 Since the pioneering work on AI by Tomasz and Hotchkiss [5] and Nealson and co-workers, 17 [6] , several AI molecules have been identified, which may be classified as follows: i) AI-1, or N-18 acyl homoserine lactones (AHLs), which are produced by over 70 species of Gram-negative 19 bacteria; ii) oligopeptides, consisting of 5-17 amino acids, which are generally produced by Gram-20 positive bacteria; iii) AI-2, a class of furanone-based AI derived from 4,5-dihydroxy-2,3-21 pentanedione (DPD), which can be produced by both Gram-positive and Gram-negative bacteria 22 and may be considered universal interspecies signalling molecules; and iv) other small molecules 23 that include the Pseudomonas quinolone signal (PQS), the Vibrio cholerae autoinducer (S)- hydroxytridecan-4-one, 3-hydroxypalmitic acid methyl ester, the AI-3 (a small AI with unknown 25 structure, used by enterohemorrhagic E. coli), bradyoxetin, and other molecules that do not fall 1 within one of the major groups [7] . 2 QS inhibition, also called quorum quenching (QQ), is considered an attractive modality of 3 therapeutic intervention for a series of reasons: i) it would overcome the conventional mechanisms 4 of resistance to antibiotics; ii) a single inhibitor could have multiple effects, being able to interfere 5 with the production of a number of virulence factors and with biofilm formation; iii) in principle, 6
anti-virulence factors should not exert an evolutionary pressure on the targeted bacterial population, 7 avoiding the emergence of resistant strains; iv) avoiding or limiting biofilm formation, QS 8 inhibitors could enhance the efficacy of existing antibiotics; v) except AI-2 members, most AI are 9 species-specific. Consequently, the narrow spectrum of activity of inhibitors should avoid the 10 disruption of beneficial microbiota [8] . It is well known that both prokaryotic and eukaryotic 11 organisms have evolved molecular mechanisms able to carry on QQ activity. The study of the 12 signal degradation systems enacted by different bacteria, plants, and mammals may lead to the 13 design of novel approaches for quenching bacterial QS [9] . Ideally, a QS inhibitor should meet the 14 following criteria: it should be a small molecule, highly specific, non toxic for eukaryotic cells, and 15 chemically stable [10] . 16 QQ compounds could be used in many fields, such as human and veterinary medicine, 17 agriculture, and aquaculture. The therapy of chronic infections, which are often due to multiresistant 18 bacterial strains, could benefit particularly from the use of antivirulence drugs [11] . By means of in 19 vitro and in vivo experiments, it has been shown that P. aeruginosa QS blockage restores the 20 immune response efficiency favouring the clearance of bacterial biofilms [12] . 21 QS systems generally offer three points of attack: the signal generation process, the signal 22 molecule, and the signal receptor [13] . During the last three decades, many natural and synthetic 23 agents belonging to the categories of small non-peptide molecules, peptides, and enzymes, have 24 been identified as QS inhibitors [14] . A very comprehensive review on QS inhibitors has recently 25 been published by Kalia [10] . The field is rapidly evolving, and many inhibitors are being 26 discovered. However, clinical applications are still lacking. To the best of our knowledge, only two 1 clinical trials on QS inhibitors have been performed. In the first one (ClinicalTrials.gov Identifier: 2 NCT00610623), the effect of azithromycin, used as a QS blocker at subinhibitory doses for the 3 prevention of P. aeruginosa ventilator-associated pneumonia was evaluated. The authors of the 4 study concluded that the major effect of QS inhibition was the selection of more virulent strains. 5
The second trial (ClinicalTrials.gov Identifier: NCT01201577), completed but with no study results 6 posted, was aimed at studying the effect of orally administered combinations of prebiotics, 7 probiotics and antibiotics on QS signalling molecules and on innate and adaptive immunity in 8 humans. 9
In this article, we focus on modern approaches for the development and validation of QS 10 inhibitors, providing the reader with a comprehensive overview of the recent literature on the 11 subject. 12 13
Strategies targeting QS signal production 14
The studies aimed to hit at targeting this step are relatively few, and the field is open for further 15 investigation. Compounds affecting the AHL biosynthesis or efflux pumps are likely to behave as 16 QQ. Substrate analogues of AI, like butyryl-S-adenosylmethionine, holo-acyl carrier protein, 17 sinefungin and L/D-S-adenosylhomocysteine can block AHL production in vitro. However, in vivo 18 experiments have not been performed, because these homologues are likely to affect the central 19 pathways of amino acid and fatty acid metabolism [15] . Small-molecule inhibitors of the AHL 20 synthase have been identified by Chung et al. [16] . The involvement of multidrug efflux pumps in 21 the QS of Burkholderia pseudomallei has been established, suggesting that this pathway could also 22 be exploited [17] . 23
Methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) is the product of the 24 pfs gene, which is highly conserved across bacterial species. This enzyme is present in bacteria but 25 not in mammals, in which its activity is performed by two different enzymes: methylthioadenosine 26 phosphorylase and purine nucleotide phosphorylase [18] . Beyond playing a crucial role in 1 maintaining homeostasis, MTAN is directly involved in the biosynthesis of AI-1 and AI-2 [19] . For 2 this reason, QS inhibitors belonging to the class of MTAN transition state analogues could be used 3 to block both AI-1 and AI-2 production in bacteria without interfering with host cell metabolism. 4
This approach has been explored by Gutierrez et al. [19] , and Longshaw et al. [20] , who found that 5 both sulphur-containing and sulphur-free MTAN transition state analogues are potent inhibitors of 6 E. coli QS. Recently, the Schramm laboratory patented two different types of transition state 7 analogues and a pharmaceutically acceptable carrier for treating bacterial infections [21] . These 8 developments indicate the interest that MTAN has aroused as a possible target for bacterial anti-9 infective drug design [1] . 10
It has been demonstrated that anthranilate (Figure 1, 1) is a precursor of the PQS (Figure 1,  11 3), which is a secondary metabolite maximally produced during the late stationary phase of growth. 12
An anthranilate analogue (methyl anthranilate) (Figure 1, 2) inhibits the production of PQS, with a 13 negative effect on the production of elastase by P. aeruginosa [22] . These data suggest that 14 pseudomonas PQS targeting may have a therapeutic value, but it must be taken into account that P. 15 aeruginosa has two other QS systems, based on N-(3-oxododecanoyl)-L-homoserine lactone (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) oxo-C12-HSL) (Figure 2, 4) and N-butyryl-L-homoserine lactone (C4-HSL) (Figure 2, 5) , 17 respectively. In this regard, it has recently been shown that eugenol (Figure 3, 6 ), the major 18 constituent of clove extract, affects P. aeruginosa QS decreasing the transcriptional activation of 19 both las and pqs systems, which together regulate the expression of numerous virulence-related 20 genes [23] . Further studies are needed to assess the relative importance of each system on the 21 virulence of P. aeruginosa, and to examine the possibility of simultaneously turning off all three 22 systems. 23 24
Strategies targeting QS signal
25 Neutralization of QS signals has been extensively investigated [24] . Biological inactivation of AHLs 1 can be achieved by enzymatic degradation or antibody-mediated inactivation of the signal molecule. AiiM lactonase on a mouse model of acute pneumonia by P. aeruginosa [26] . The study supports 10 the therapeutic potential of AHL lactonases in therapy, demonstrating that AiiM is a potent inhibitor 11 of P. aeruginosa QS and reduces bacterial virulence. The use of this molecule could represent a 12 new strategy to cure chronic pulmonary infections by multiresistant strains. However, the 13 problematic issue is the way of administration: in their experiments, the authors used lactonase-14 overexpressing plasmid vector-transformed P. aeruginosa to infect mice. This technique can be a 15 good experimental tool, but, of course, it is not of any use for therapeutic purposes. The authors 16 suggest two possible solutions to this impasse: the genetic modification of probiotics, or the local 17 administration of the purified AiiM protein. In both cases, the authors agree that further studies are 18 needed to evaluate the possibility of developing AiiM lactonase into a drug molecule. 19
One of the best studied acylases is the PvdQ protein, a member of the N-terminal 20 nucleophile hydrolase superfamily. This enzyme is produced by the P. aeruginosa PAO1 strain, 21
suggesting that it may participate to the regulation of its own QS-dependent pathogenic potential. 22
PvdQ behaved as a QQ in vitro in a number of phenotypic assays in which the pvdQ gene was 23 overexpressed in P. aeruginosa, and its activity was demonstrated in vivo in a Caenorhabditis 24 elegans model [27] . The development of the molecule has reached the stage of the production of a 25 stable and inhalable powder formulation for the treatment of P. aeruginosa pulmonary infection 1 [28] .
2 Paraoxonases (PON) are a group of Ca 2+ -dependent esterases with AHL lactonase activity 3 widely conserved in mammals, but not present in chicken and fish [29] . In humans, the family 4 comprises three members, whose genes are located on chromosome 7: PON1 and PON3, mainly 5 expressed in liver and kidney, and PON2, expressed in various tissues but not present in plasma 6 [30] . These enzymes are supposed to play an important role in the defence against the formation of However, their value for clinical purposes needs to be assessed. It can be expected that they will 20 find application in the treatment of skin and airway infections, and in the inhibition of bacterial 21 biofilm formation on catheters and prosthetic devices. 22 23
Antibodies 24
Most AHLs exert potent biochemical effects, such as induction of apoptosis and modulation of NF-25 κB activity, behaving as small-molecule toxins on mammalian cells. Consequently, specific 26 antibodies can achieve the dual purpose of neutralizing both the QS activity and the toxic effect. 1
The immunological approach includes the induction of antibodies by vaccination, and the 2 administration of preformed mono-or poly-clonal antibodies. 3
Following the first demonstration of the efficacy of vaccination with a homoserinelactone-4 carrier protein conjugate in a mouse model of P. aeruginosa lung infection by Miyairi et al. [36] , the 5 possibility to produce protective antibodies has been extensively investigated, especially by the 6 Janda laboratory at The Scripps Research Institute [37] [38] [39] . The attractivity of this approach is based 7 on the high evolutionary conservation of AI, their extracellular distribution, and the established 8 knowledge of antibody pharmacodynamic and kinetic properties. The chemical structure and the 9 low molecular weight make the AI poor antigens, which could be more properly defined haptens [7] . 10
The efficacy of the immunopharmacotherapeutic approach to the inhibition of QS has been 11 were characterized by high sensitivity (100-1000 times higher than that of any published antibodies 20 raised to the same target). Their protective effect was assessed in a slow-killing model of C. 21 elegans, and in a mouse model of P. aeruginosa infection [41] . These findings provide a strong 22 foundation for further investigations of the potential of AHL monoclonal antibodies in the 23 immunopharmacotherapy of antibiotic resistant strains of P. aeruginosa. 24 25 4. Strategies targeting autoinducer-receptor interaction and/or receptor-1 mediated signal. 2 The possibility to inhibit the expression of QS signal receptors by means of antisense RNAs has 3 been demonstrated by Hirakawa et al. [42] . For a comprehensive review on the inhibition of signal 4 detection, the reader is referred to [43] . In the following paragraphs, we will discuss some recent 5 insights on the QS of S. aureus and P. aeruginosa that may suggest the possibility of interfering 6 with the receptor side of the system. 7
The clarification of the QS system in Gram-positive bacteria allowed the identification of 8 molecules inhibiting different steps of the mechanism. The QS system of S. aureus, which is the 9 most studied, consists of the accessory gene regulator (agr) locus, which is composed of two 10 transcripts called RNAII and RNAIII, driven by the P2 and P3 promoters, respectively. The RNAIII 11 transcript is the effector of the agr response, which up-regulates a number of toxins and multiple 12 exoenzymes (proteases, lipases, and nucleases), and down-regulates the expression of numerous 13 surface protein genes. The RNAII transcript is an operon of four genes, agrBDCA. AgrD is the 46 14 aminoacid precursor of the secreted AI, a cyclic thiolactone peptide (AIP) of 7-9 aminoacids, which 15 is processed, cyclized and exported through the transmembrane protein AgrB. The extracellular AI 16 binds to AgrC, the transmembrane receptor, which is a histidine kinase that following the binding 17 phosphorylates the AgrA cytoplasmic response regulator, activating the P2 and P3 promoters. More 18 advanced strategies targeting S. aureus virulence gene regulation make use of inhibitors of the 19 sensor kinase AgrC, of the transcriptional activator AgrA, or of the RNAIII [44] . 20
Due to allelic variations within the agr gene system, S. aureus can be subdivided into four 21 agr specific groups, agr I−IV, each secreting a distinct AIP with different primary amino acid 22 sequence. Most cross-group AIP-AgrC interactions are inhibitory, with AIPs activating their 23 cognate receptors and competitively inhibiting non-cognate receptors. The competitive AIP 24 inhibition constitutes a promising therapeutic approach for attenuating S. aureus infections. 25
Recently, it has been demonstrated by in vitro experiments that oxidized low-density lipoproteins 1 bind all four S. aureus agr AIPs and antagonize agr signalling by each agr allele [45] . 2
Molecules interfering with the S. aureus agr system have been obtained by a marine 3
Photobacterium. Due to the structural similarity of these molecules, called solonamides, to the agr 4 AI, the proposed mechanism of action is competitive inhibition [46] . The solonamides are the first 5 reported natural antagonists with a structure resembling that of native S. aureus AI. Another natural 6 product, hamamelitannin, obtained from Hamamelis virginiana (witch hazel), was identified as an 7
inhibitor of RNAIII and δ-hemolysin production in S. aureus by Kiran et al [47] . 8
Two of the three P. aeruginosa QS systems consist of the lasRI and rhlRI genes, where 9
LasR and RhlR belong to the LuxR family of transcriptional regulators that specifically bind to N-10 (3-oxododecanoylhomoserine lactone (3-oxo-C12-HSL) and N-butanoylhomoserine lactone (C4-11 HSL), respectively [48] . The las and rhl systems regulate over 10% of the P. aeruginosa genome 12
and are hierarchically organized. The 3-oxo-C12-HSL signal is the key factor that exerts 13 transcriptional control over lasI, rhlR, rhlI and the genes of the third system, the PQS system. observed that, independently of its effects on the production of QS signal molecules, RsaL directly 22 represses 120 genes, many of which code for virulence and antibiotic resistance, and activates 10 23 genes (undefined) [50] . 24
A recently identified novel LasR-specific antiactivator is QslA, which binds to LasR and 25 prevents it from binding to its target promoter [ QslA and demonstrated that its mechanism of action consists in the disruption of LasR dimers by 3 occupying the LasR dimerization interface, which is a previously unknown mechanism of QS 4 inactivation [53] . 5
Other QS negative regulators produced by P. aeruginosa are QscR, which is an "orphan" 6 receptor activated by the 3-oxo-C12-HSL signal [54] , and QteE, which reduces LasR protein 7 stability without affecting LasR transcription or translation [55] . It has been shown that negative 8 regulation of QS by QteE and QscR has a major impact on the absolute and relative fitness of P. 9
aeruginosa [56] . The possibility to interact with these regulator systems for therapeutic purposes is 10 currently being investigated. In a recent paper, Weng et al. report on a novel QS inhibitor, called 11 C2, which causes a 375.4% upregulation of the qscR gene, resulting in the attenuation of elastase 12 and protease activity, swarming motility and biofilm formation in the P. aeruginosa strain 13 PAO1[57]. 14 The P. aeruginosa PQS system may be inhibited by anthranilic acid halogenated analogues, 15 whose development, however, has not been pursued [58; 59] . However, novel insights on the 16 structure of PqsE, a product of the pqs operon, could lay the foundations for the computer-aided 17 design of PqsE inhibitors [60] . Antagonists of the PqsR were reported for the first time in 2012 [61] , 18 and a peculiar mechanism of functional inversion of a PqsR antagonist has been recently described 19 by Lu et al. [59] . These authors observed that compound 1 (Figure 4, 7) , which behaves as a pure 20
PqsR antagonist in an E. coli reporter gene assay, displayed a dose-dependent agonistic activity 21 when tested in a P. aeruginosa functional assay. This unusual behaviour can be explained by the 22 transformation of compound 1 into compound 2 (Figure 4, 8) . A product of the pqs operon, the 23 enzyme PqsH, which is present in P. aeruginosa only, carries out the transformation. The analysis 24 of the molecular structure of the antagonist and of the chemical modification that turns it into an 25 agonist allowed the synthesis of a small library of substituted compounds, among which compound 26 3 (Figure 4, 9) showed high potency in the E. coli reporter gene assay, but retained its antagonistic 1 activity in P. aeruginosa without displaying any agonistic activity [59] . In a recent paper, Ilangovan Farnesol (Figure 5, 10) is a sesquiterpene alcohol produced by Candida albicans and 7 present in the essential oils of citrus fruits. Beyond its activity as fungal QS molecule [63] , it affects 8 PQS production by inhibiting the transcription of the pqs operon. According to the proposed model, 9
farnesol stimulates PqsR interaction with a pqsA promoter fragment in the region of the PqsR 10 binding site, causing a non-productive interaction with the pqsA promoter that does not lead to 11 transcriptional activation of the pqsA-E operon [64] . The result is the impairment of production of 12 pyocyanin, a pseudomonas QS-controlled virulence factor. Farnesol is an interesting molecule, 13 because it is devoid of toxic effects, non mutagenic, and affects biofilm formation by C. albicans, 14
Streptococcus mutans, and Staphylococcus aureus [65] . For an interesting discussion on the 15 interactions between C. albicans and P. aeruginosa, the reader is referred to [66] . However, farnesol Following the original discovery of the anti-QS activity of natural halogenated furanones 6 (fimbrolides) isolated from Delisea pulchra, many analogues have been and are produced by 7 chemical synthesis [68] . Traditional synthetic approaches usually yield small panels of synthetic AI 8 analogues, some of which have proved potent QS modulators. A significant improvement of the QS 9 disrupting activity has been recently obtained by the combination of fimbrolides with NO-donor 10 molecules in hybrid compounds (Figure 6, 11, 12) [ analogues of (4S)-4,5-dihydroxy-2,3-pentanedione (DPD), called C4-alkoxy-HPDs, which are more 17 potent than natural AI-2 molecules. These findings highlight how manipulation of the DPD scaffold 18 can provide valuable tools for in-depth studies of the ligand-receptor interactions involved in AI-2-19 mediated QS, and lay the foundation for future chemical structure-based studies aimed at 20 identifying and developing antagonistic analogues [70] . For a comprehensive review focused on 21 chemical methods including combinatorial synthesis, affinity chromatography, and electrochemical 22 sensing of QS signals, the reader is referred to [71] . 23 24
Computer-aided investigations. 25
Among modern approaches, high throughput screening maintains its validity yielding hit molecules 1 often based on new molecular scaffolds [72, 73] , but in silico investigations are considered more 2 convenient in terms of cost, speed of execution, and potency, being able to screen up to millions of 3 compounds. Examples of results obtained by the use of structure-based virtual screening are the 4 recent identification of inhibitors of P. aeruginosa QS from a natural-derivative database [74] , and 5 from the ChemBridge library [75] . The in silico approach has been used not only for screening 6 purposes, but also for studying QS dynamics [76] , and to identify bacterial species that contained 7 both QS and aromatics degrading systems, in order to acquire information for developing novel bio-8 processing techniques [77] . 9
An innovative approach is the production by Schaadt et al. of a multi-level logical model 10 based on computational analysis of a combined regulatory and metabolic network for the three P. In order to get a better insight into the regulation of S. aureus QS system, Audretsch et al 18 used an innovative approach to model the whole system [79] . Instead of creating a mathematical 19 model, these authors used a Boolean network of nodes centred on the agr locus of S. aureus. The in 20 silico node activation patterns were compared with gene activation patterns obtained from 21 microarray, northern blot, and transcriptome data. The network can easily be manipulated and 22 studied, and has two different steady states: one representing an invasive, toxic phenotype, and the 23 other representing a biofilm producing phenotype. By manipulating the nodes of the simulated 24 network, the model may be used to test theories about mutant strains and to predict the effects of 25 QS inhibitors. 26 Sahner et al. have recently devised a novel approach based on the combination of in silico and 1 biophysical methods (surface plasmon resonance, isothermal titration calorimetry, saturation 2 transfer difference, and nuclear magnetic resonance) for the development of P. aeruginosa QS 3 inhibitors. They demonstrated that the use of the two methods in combination represents a powerful 4 complement to co-crystallography, and allows the rapid and efficient development of inhibitors. By 5 using this combination technique, these authors identified an irreversible inhibitor that covalently 6 binds to the active site of PqsD, which mediates the formation of the precursor of the Pseudomonas 7 quinolone signal (PQS) [80] . 8 9
Nano-and micro-technologies. 10
Nanotechnologies can be used to direct bacterial communication, by means of "nanofactory"-loaded 11 biopolymer capsules placed at the midst of bacterial populations [81, 82] . It can be expected that this 12 type of instruments, once developed, could be used to assist or replace the activity of the classic 13 antibiotics, and to extend our knowledge of the QS systems and modulate them, so as to direct the 14 microbiome to operate in a host-friendly manner. The possibility to modulate QS has also been 15 demonstrated by means of titanium dioxide bead coated with AHL [83] . The implications of these 16 experiments include the production of medical devices (catheters, joint and cardiac prosthetic 17 devices) with coated surfaces able to interrupt QS signalling and to avoid biofilm formation. 18
The application of novel technologies derived from quite a different field like 3D printing to 19 study bacterial interactions opens new horizons. By means of a microscopic three-dimensional (3D) 20 printing strategy that enables multiple populations of bacteria to be organized within essentially any 21 3D geometry, including adjacent, nested, and free-floating colonies, it has been possible to obtain 22 the rapid growth of fully enclosed cellular populations that release a number of biologically active 23 molecules, including polypeptides, antibiotics, and QS signals. Using this approach, Connell et al. 24 showed that picoliter-volume aggregates of S. aureus can display substantial resistance to β-lactam 25 antibiotics by enclosure within a shell composed of P. aeruginosa [84] . The technique takes 26 advantage of thermally set gelatine mixtures as a reagent for micro-3D printing, which provides the 1 ability to print enclosures around any bacterial cell of interest suspended within the hydrogel 2 matrix. In the words of the authors, this manufacturing strategy provides a versatile base for 3 exploring the mechanisms involved in cell communication, which allow bacterial adaptation to the 4 natural environment by means of social behaviour. This technology could perhaps be exploited at 5 its best if coupled with the use of bacteria programmed to sense and destroy highly pathogenic 6 species. 7 8
Bacterial bio-engeneering 9
In a recent paper, Gupta et al. describe the engineering of sentinel E. coli cells, capable of 10 specifically detecting the QS AI molecule 3OC 12 HSL, produced by P. aeruginosa, and then to 11 synthesize and secrete the chimeric bacteriocin CoPy, specific for PAO1 P. aeruginosa [85] . The 12 engineering of E. coli consists of three interconnected modules: the detection module, which is 13 activated by the PAO1 QS signal; the destruction module, which produces the toxin; and the 14 secretion module that allows the secretion of CoPy. The effectiveness of the system was assessed by 15 experiments in which the two bacterial species were co-cultured on semi-solid agar plates. The 16 system has two advantages: first, it is possible to change the type of toxin produced; second, in the 17 absence of the pathogen, the system remains in stand-by, but the production starts immediately after 18 the detection of the pathogen. 19
Bacterial QS is also involved in extracellular cell death and in the action of antibiotics, 20 through its interference in a system also called "addiction module", which can be found in many 21 different Gram-positive and -negative bacteria. The system, which has mainly been studied in E. 22 coli, consists of a pair of genes whose products are a stable toxin and an unstable antitoxin, which 23 prevents the lethal action of the toxin [86] . In this situation, bacterial survival depends upon the 24 continuous production of the short-lived antitoxin, to which the cell is "addicted". It has been 25 shown that in E. coli the effect of some antibiotics such as rifampicin, chloramphenicol, 26 spectinomycin, and nalidixic acid is due to the inhibition of the antitoxin production, and that this 1 action is dependent upon the presence in the culture of high concentrations of a QS mediator called 2 "extracellular death factor" (EDF) [87, 88] . The E.coli EDF is a linear pentapeptide with the amino 3 acid sequence Asn-Asn-Trp-Asn-Asn, which is able to induce programmed cell death also in 4 conditions of cell stress, like amino acid starvation or DNA damage. Recently, it has been shown 5 that one hexapeptide produced by Bacillus subtilis and three peptides, one nonapeptide and two 6 hexadecapeptides produced by P. aeruginosa, have the same effect of the E. coli EDF on E. coli 7 cultures [89] . These findings establish the existence of a growing family of EDFs that behave as AI 8 and exert both intra-and inter-specific activity. These molecules may provide a basis for the 9 development of a new class of antibacterials, which could synergize with antibiotics. 10 11
Expert opinion 12
Despite the huge amount of molecules so far discovered that inhibit the QS mechanisms, the 13 potential of QS inhibition as a future treatment strategy has yet to be fully assessed. In addition, 14 there are obstacles, some obvious, others in the process of being recognized, which hinder the 15 transformation of QS inhibitors into real drugs. The most obvious roadblock, which QS inhibitors 16 share with antibiotics, is the lack of interest of pharmaceutical companies to bear the costs related to 17 the development of hits into drugs that are inevitably bound to have a very limited market. This 18 issue is critical to the future of the treatment of infectious diseases in this so-called post-antibiotic 19 era. In accordance with what has already been proposed for the development of new antibiotics and 20 drugs for neglected diseases, probably the best way to overcome the impasse is the union of skills 21 and funds from private companies, academia and public institutions. In the short term, the 22 knowledge gained so far, especially that concerning plant-derived inhibitors, could perhaps be used 23 in the field of dietary advice and food supplements. Since the pioneering work of Givskov et al. [90] 24 reporting the inhibitory effect of brominated furanones from the Australian macroalga D. pulchra 25 on Serratia liquefaciens QS-mediated swarming, many plant-derived inhibitors have been 26 identified. For a comprehensive review, the reader is referred to [91] . To improve the characteristics 1 of natural derivatives, a number of synthetic molecules have also been developed, and more than 40 2 have been patented [92, 93, 15, 1] . However, we are still far from having a licensed drug available on 3 the market, if we exclude some antibiotics, such as azithromycin, ceftazidime and ciprofloxacin, 4 which at subinhibitory concentrations block the expression of QS-regulated virulence factors in P. 5 aeruginosa [94] . In this regard, we must stress the importance of distinguishing between the direct 6 toxic effect of a substance and its inhibiting activity on QS. To this aim, it is essential to verify the 7 effect of QS inhibitors on bacterial viability by using sensitive methods and appropriate controls. In 8 the case of pyrogallol, it has recently been shown that its previously highlighted QS-disrupting 9 activity is a side effect of the peroxide production induced by this compound rather than true QS 10 inhibition [95] . According to Defoirdt et al., many of the results obtained in experiments that make 11 use of QS signal molecule reporter strains may be questioned, due to the possibility that the tested 12 compounds may be toxic to the reporter strains [96] . These authors suggest that toxicity tests more 13 stringent than those implemented so far should be used on molecules proposed as QS inhibitors. 14 Another emerging problem is the possibility that QS inhibitors can select more virulent 15 strains. Resistance to QS inhibitors has been studied by means of mathematical models [97] [98] [99] [100] [101] , and 16 of in vitro experiments [102] [103] [104] . Bacterial resistance to brominated furanones is mediated by 17 increased efflux activities. As this kind of resistance overlaps with resistance to antibiotics, the 18 treatments with antibiotics endowed with a strong selective pressure may result in improved 19 resistance to antivirulence compounds (and perhaps vice versa). The finding that some strains 20 isolated from cystic fibrosis patients are resistant to QS inhibitors, corroborates this hypothesis. 21
Additional clinical evidence of the ability of bacteria to evolve resistance to QQ compounds was 22 provided by studying the resistance of P. aeruginosa isolated from urine, blood, and catheter tip 23 specimens obtained from Mexican children [104] . 24
Other in vivo and in vitro results reported by Kohler et al. demonstrate that QS inhibition 25 interferes with natural selection towards reduced virulence, and therefore may increase the 26 prevalence of more virulent genotypes [105] . Some concerns about the widespread use of QQ 1 compounds as part of an antibacterial therapy have been raised by the possibility that targeting a 2 specific bacterial group may predispose the patient to infection by other groups. For example, in S. 3 aureus, but not in S. epidermidis, biofilm production is under the agr system control. In this 4 situation, agr inhibition would favour S. epidermidis, suggesting that agr antagonists would not be 5 indicated for the control of staphylococcal biofilm infections [106] . 6
Interestingly, resistance to QQ compounds may be enhanced by the complex interplay of 7 bacteria with bacteriophages, and it seems that QS constitutes a significant, but so far overlooked, 8 determinant of bacterial susceptibility to phage attack [107] 9
The AHLs often exert toxin-like effects on mammalian cells. Hence, neutralizing antibodies 10 would achieve the double goal of disrupting bacterial QS and protecting the host from toxicity. As 11 discussed above, the disrupting efficacy of antibodies was demonstrated both in P. aeruginosa and 12 S. aureus QS systems. Based on these results, and taking into account the evolutionary high 13 conservation and extracellular distribution of AI, QS can be considered a good target for active and 14 passive immunotherapy approaches [39] . However, here again some caution is necessary. In a recent 15 paper, Michael-Gayego et al. report that SilCR, a QS peptidic AI produced by Group A (GAS) and 16 G streptococci, effectively decreases bacterial virulence in vivo. The effect was also observed in 17
SilCR-vaccinated mice, which developed a more severe disease than non-vaccinated ones [108] . The 18 paradox is that SilCR is the product of a gene belonging to the streptococcal invasion locus, sil, 19 which is a virulence factor involved in GAS spreading into deeper tissues. This is perhaps the first 20 demonstration that antibodies directed against a bacterial component increase the severity of the 21 disease. On the other hand, QS activation can be used to improve the antigenicity and the efficacy 22
of an E. coli bacterin preparation to be used for vaccination purposes, as reported by Sturbelle et al. 23 [109] . These examples underline both the potentials of QS exploitation for therapeutic purposes and 24 the need to clarify all aspects of the involved mechanisms. 25
In conclusion, QS inhibition can be considered a promising strategy against infections, especially 1 those associated with biofilm formation, and the discovery of new inhibitory molecules is rapidly 2 progressing. However, to identify a new molecule as a pure QS inhibitor, it is necessary to develop 3 more standardized methods of evaluation, with particular attention to rule out direct toxicity that 4 may mimic a QQ effect. Moreover, concerns about the possible emergence of resistance and 5 adverse effects resulting from the alteration of the microbiome must be properly addressed in-depth . 6 In our view, the current challenge in the field of QS research is not so much to find new inhibitory 7 molecules, but to refine and deepen our knowledge on the QS-based interactions between different 8 bacterial species and between bacteria and the host. Important issues that need further investigation 9
are the impact of QS on the social evolution of bacteria, as well as the impact of bacterial social-10 driven evolution on the infection of the host. Studies performed in mice [110] and humans [111] 11 demonstrated that cultures containing mixtures consisting of QS cooperators, i.e. autoinducer-12 producing cells, and cheats, i.e. cells that do not produce autoinducers but benefit of cooperator-13 produced autoinducers, are less virulent than cultures containing pure cooperators, suggesting that 14 asocial cheats could be exploited to exert a potential therapeutic role [112] . An interesting discussion 15 on bacterial cooperation and its possible relevance in the clinical field can be found at [113] . 16 The last, but not least important aspect that must be taken into account is that so far the 17 transformation of laboratory results into viable drugs is almost non-existent [114] . This situation is 18 not expected to improve in the near future, because, as is the case for antibiotics, market forces are 19 insufficient to drive the development of antibacterial drugs based on new scaffolds. The need for 20 long-term, huge investments, and the prospect to see the novel drug indications limited to small 21 number of cases, made many large pharmaceutical companies to quit antibiotic discovery for more 22 profitable therapeutics [115] . The political, medical and public concern about the rising innovation 23 gap in 2009 prompted the U.S. and European Community presidencies to establish a Transatlantic 24 Task Force to address antimicrobial resistance, and the Infectious Diseases Society of America 25 called for a global commitment to develop 10 novel antimicrobials by 2020 [116] . We can envisage 26 that in the near future the synergy between new technical developments and public-private 1 industrial partnerships will bring into being a new harvest of badly needed novel antimicrobials, 2 including antibiotics and antivirulence agents. The most recent approaches in the field of QS research span from mathematical modelling of the 18 QS systems to the combination of in silico and biophysical methods, to the creation of hybrid 19 compounds by fusing fimbrolides with NO-donor molecules, and to the exploitation of the 3D 20 printing technology to study short-distance interspecific bacterial interactions. 21
22
The impact of the social behaviour of bacteria on the microbiome and on the establishment of 23 infections needs further investigation. Some concerns are emerging following the someway 24 unexpected discovery that QS inhibitors can exert a selective pressure favouring the establishment 25 of more virulent strains. This aspect should be thoroughly investigated before any QS inhibitor is 1 licensed and put on the market. 23   24   25   26  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  Figure 1  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  Figure 2  41  42  43  44  45  46  47  48  49  50  Figure 3 6  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  Figure 4  34  35  36  37  38  39  40  41  42  43  44  Figure 5  45  46  47  48  49  50 
